Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations ...

Pfizer (NYSE:PFE) shares traded in the red on Friday, making it the seventh straight day of losses. The stock is down 0.43% at $27.53. PFE has fallen 31.63% in the last 12 months and 3.1% in the ...

Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research ...

Pfizer (PFE) stock in focus as the company sells its entire 7.3% stake in Haleon (HLN) for $3.24B. Read more here.

Equities research analysts at Zacks Research reduced their Q2 2026 earnings per share (EPS) estimates for Pfizer in a report issued on Thursday, March 20th. Zacks Research analyst K. Shah now ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...

Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...

Community Bank N.A. cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 26.5% in the fourth quarter, according to its ...

VOV.VN - Pfizer Vietnam Company Limited (Pfizer VN) and Vietnam Vaccine Joint Stock Company (VNVC) signed a Memorandum of ...

Its financials aren't in bad shape, and while the stock has been struggling, now could make a great time to load up on it. Here are three reasons why Pfizer could prove to be a steal of a deal ...